UBS lowered the firm’s price target on QuidelOrtho (QDEL) to $29 from $45 and keeps a Neutral rating on the shares. Margins are on track and guidance was reaffirmed amid a smaller-than-expected impact from tariffs, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QDEL:
- QuidelOrtho Reports Strong Q1 2025 Financial Results
- Closing Bell Movers: Arm sinks over 10% as guidance falls short
- QuidelOrtho says will be taking price on a ‘selective basis as we can’
- QuidelOrtho says capital allocation priority remains paydown of debt
- QuidelOrtho says company actions ‘sufficient’ to mitigate tariff impacts